| Literature DB >> 23056544 |
Karim Helmy1, John Halliday, Elena Fomchenko, Manu Setty, Ken Pitter, Christoph Hafemeister, Eric C Holland.
Abstract
Post-transcriptional regulation of gene expression contributes to the protein output of a cell, however, methods for measuring translational regulation in complex in vivo systems are lacking. Here, we describe a sensitive method for measuring translational regulation in defined cell populations from heterogeneous tissue in vivo. We adapted the translating ribosome affinity purification (TRAP) methodology to measure the relative occupancy of individual mRNA transcripts in translating ribosomes in the Olig2-positive tumor cell population in a genetically engineered mouse model (GEM) of glioma. Global measurement of paired ribosome-bound and total cellular mRNA populations from tumor cells in vivo identified a broad distribution of relative ribosome occupancies amongst mRNA species that was highly reproducible across biological samples. Comparison of the translation state of glioma cells to non-transformed oligodendrocyte progenitor cells in normal brain identified global alteration of translation in tumor, and specifically of genes involved in cell division and synthetic metabolism. Furthermore, investigation of alteration in steady state translational efficiencies upon loss of PTEN, one of the most frequently mutated and deleted tumor suppressors in glioma, identified differential translation of proteins involved in cellular respiration, canonically regulated by PI3K/Akt signaling, and cellular glycosylation profiles, deregulation of which is known to be associated with tumor progression. Application of the translation efficiency profiling method described here to other biological contexts and conditions would extend our knowledge of the scope and impact of this important mode of gene regulation in complex in vivo systems.Entities:
Mesh:
Substances:
Year: 2012 PMID: 23056544 PMCID: PMC3463531 DOI: 10.1371/journal.pone.0046965
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1GBM is a heterogeneous tumor composed of multiple cell types, including both tumor and stromal cells.
(A) Immunohistochemical staining of mouse PDGF-driven glioma identified multiple tumor regions composed of different cell types. (B) PDGF-HA oncogene expressed from tumor cells colocalized with Olig2 staining by IHC. (C) FACS analysis of tumors generated in Olig2-eGFPL10a mice with PDGF-RFP bicistronic retrovirus identified tumor cells as Olig2+. Scale bar, 100 µm.
Figure 2In vivo quantification of ribosome-bound and total RNA levels revealed a broad range of ribosome recruitment efficiencies amongst mRNA transcripts.
(A) Distribution of mRNA expression in ribosome-bound and total RNA pools from PDGF-driven glioma identified differential TE (N = 4). (B) TE values for each biological replicate (black points) plotted with the average of the other three replicates (red line) demonstrated reproducibility of measurements. (C) Signal-to-noise ratios of TE measurements (blue bars) identified range of high confidence measurements relative to a normal distribution (red line). (D) GSEA identified statistical overrepresentation of defined gene ontologies amongst efficiently and inefficiently translated genes. Black bars represent distribution of mRNAs from indicated geneset amongst all genes ranked by signal to noise ratio (top panel). Red line represents GSEA output enrichment score. R = Pearson correlation coefficient.
Figure 3Translation efficiency was altered in glioma compared to normal brain OPCs.
(A) Changes in ribosome-bound mRNA correlated somewhat with changes in total cellular RNA between tumor and normal brain OPCs (N = 4). (B) Alterations in TE between tumor and normal brain were reproducible, exceeding average replicate error. (C) Genesets associated with cell division and biosynthetic pathways predominated amongst GOSlim Biological Process genesets most enriched for transcripts translationally upregulated in Olig2+tumor cells compared to normal brain OPCs. Enrichment plots for chromosome organization and mitosis genesets shown. (D) Genesets associated with synaptic signaling predominated amongst GO Biological Process genesets most enriched for transcripts translationally downregulated in Olig2+tumor cells compared to normal brain OPCs. Enrichment plots for transmission of nerve impulse and synaptic transmission shown. NES = Normalized Enrichment Score. R = Pearson correlation coefficient.
Figure 4PTEN loss altered the translation state of glioma cells.
(A) TE measurements of PTEN WT and PTEN deleted tumors were very similar (N = 4). (B) Changes in both total RNA and TE contributed to alteration in ribosome-bound RNA caused by PTEN loss. (C) GO genesets associated with oxidative phosphorylation were amongst those most enriched for transcripts translationally downregulated in PTEN-deleted vs PTEN WT tumors. Enrichment plots for electron transport chain and cellular respiration genesets shown. (D) Genesets associated with glycolysis predominated amongst GO genesets most enriched for transcripts translationally upregulated in PTEN-deleted vs PTEN WT tumors. Enrichment plots shown for genesets for hydrolase activity acting on glycosyl bonds and transferase activity transferring glycosyl bonds. NES = Normalized Enrichment Score. R = Pearson correlation coefficient.
PDGF+Cre vs. PDGF only tumors; genes with >2-fold downregulated TE and FDR<0.05.
| PDGF+Cre vs. PDGFLog2 Change | ||||
| Gene Symbol | Description | PC-P IP | PC-P Total | PC-P TE |
|
| ubiquitin protein ligase E3A | −2.71 | −0.66 | −2.05 |
|
| chaperonin containing Tcp1, subunit 5 (epsilon) | −3.26 | −1.22 | −2.03 |
|
| solute carrier family 3 (activators of dibasic and neutral amino acid transport), member 2 | −2.04 | −0.02 | −2.02 |
|
| EP300 interacting inhibitor of differentiation 1 | −3.77 | −2.00 | −1.77 |
|
| proliferating cell nuclear antigen | −2.61 | −0.86 | −1.75 |
|
| isopentenyl-diphosphate delta isomerase | −1.91 | −0.20 | −1.71 |
|
| ring finger and SPRY domain containing 1 | −2.37 | −0.66 | −1.71 |
|
| similar to coiled-coil domain containing 72 | −2.25 | −0.72 | −1.53 |
|
| fatty acid binding protein 7, brain | −2.60 | −1.10 | −1.50 |
|
| SRY-box containing gene 2 | −2.73 | −1.27 | −1.46 |
|
| similar to ATP synthase, H+ transporting, mitochondrial F0 complex | −2.63 | −1.16 | −1.46 |
|
| TAF9 RNA polymerase II, TATA box binding protein (TBP)-associated factor | −1.86 | −0.43 | −1.43 |
|
| ATP-binding cassette, sub-family E (OABP), member 1 | −1.65 | −0.24 | −1.40 |
|
| HECT, UBA and WWE domain containing 1 | −2.21 | −0.82 | −1.40 |
|
| glial cell line derived neurotrophic factor family receptor alpha 1 | −0.94 | 0.43 | −1.37 |
|
| NADH dehydrogenase (ubiquinone) 1 beta subcomplex 4 | −2.03 | −0.68 | −1.35 |
|
| phosphatidylinositol 3-kinase, catalytic, alpha polypeptide | −1.77 | −0.42 | −1.34 |
|
| ubiquitin-conjugating enzyme E2N | −2.04 | −0.72 | −1.33 |
|
| stathmin 1 | −2.21 | −0.89 | −1.32 |
|
| ubiquitin domain containing 2 | −1.89 | −0.61 | −1.29 |
|
| kelch-like 13 | −1.65 | −0.37 | −1.28 |
|
| zinc finger protein 647 | −1.74 | −0.46 | −1.28 |
|
| upregulated during skeletal muscle growth 5 | −2.03 | −0.76 | −1.28 |
|
| RIKEN cDNA 2610528E23 gene | −1.73 | −0.45 | −1.27 |
|
| junction adhesion molecule 3 | −2.31 | −1.06 | −1.25 |
|
| Max interacting protein 1 | −2.59 | −1.34 | −1.24 |
|
| heterogeneous nuclear ribonucleoprotein A2/B1 | −2.51 | −1.30 | −1.22 |
|
| sorting nexin 1 | −2.12 | −0.94 | −1.19 |
|
| signal peptidase complex subunit 2 homolog | −1.78 | −0.60 | −1.18 |
|
| N-myc downstream regulated gene 2 | −1.39 | −0.21 | −1.18 |
|
| sorting nexin 3 | −2.04 | −0.86 | −1.17 |
|
| predicted gene, OTTMUSG00000007855 | −2.58 | −1.41 | −1.17 |
|
| succinate dehydrogenase complex, subunit D | −1.44 | −0.28 | −1.16 |
|
| RIKEN cDNA 1500003O22 gene | −1.61 | −0.47 | −1.14 |
|
| taurine upregulated gene 1 | −2.05 | −0.93 | −1.13 |
|
| protein-L-isoaspartate (D-aspartate) O-methyltransferase 1 | −1.82 | −0.69 | −1.12 |
|
| chromatin modifying protein 5 | −2.08 | −0.96 | −1.12 |
|
| SLAIN motif family, member 1 | −0.78 | 0.34 | −1.12 |
|
| cytochrome c | −2.06 | −0.94 | −1.12 |
|
| similar to oxidative stress responsive 1 | −1.51 | −0.40 | −1.11 |
|
| zinc finger with KRAB and SCAN domains 3 | −2.02 | −0.92 | −1.11 |
|
| similar to G protein gamma-5 subunit | −2.02 | −0.93 | −1.09 |
|
| crystallin, zeta (quinone reductase)-like 1 | −1.68 | −0.60 | −1.08 |
|
| Ras suppressor protein 1 | −2.06 | −0.98 | −1.08 |
|
| similar to polymerase (RNA) II (DNA directed) polypeptide K | −1.35 | −0.28 | −1.07 |
|
| suppression of tumorigenicity 13 | −1.27 | −0.22 | −1.05 |
|
| similar to brain protein 44 | −2.16 | −1.10 | −1.05 |
|
| general transcription factor II E, polypeptide 2 (beta subunit) | −1.66 | −0.61 | −1.05 |
|
| small proline-rich protein 2A | −1.46 | −0.41 | −1.05 |
|
| zinc finger protein 161 | −1.85 | −0.81 | −1.04 |
|
| programmed cell death 5 | −1.74 | −0.72 | −1.02 |
|
| cofilin 2, muscle | −1.87 | −0.85 | −1.02 |
|
| nitrilase family, member 2 | −1.76 | −0.74 | −1.02 |
|
| cytochrome c oxidase subunit VIIb | −1.60 | −0.59 | −1.01 |
PDGF+Cre vs. PDGF only tumors; genes with >2-fold upregulated TE and FDR<0.05.
| PDGF+Cre vs. PDGFLog2 Change | ||||
| Gene Symbol | Description | PC-P IP | PC-P Total | PC-P RRO |
|
| galactose-4-epimerase, UDP | 1.38 | 0.28 | 1.10 |
|
| DNA segment, Chr 9, ERATO Doi 402, expressed | 1.59 | 0.40 | 1.19 |
|
| tetratricopeptide repeat domain 14 | 0.66 | −0.64 | 1.30 |
|
| kelch domain containing 9 | 1.51 | −0.19 | 1.70 |